Teva Pharmaceuticals USA is recalling approximately 648,222 bottles of Valsartan and Valsartan with Hydrochlorothiazide (HCTZ) tablets, used to treat high blood pressure. These medications were recalled because an impurity classified as a probable human carcinogen was found in the active ingredient used to make the tablets. No injuries or specific illnesses have been reported to date, but the medication was distributed nationwide throughout the United States, Puerto Rico, and Hawaii.
The drug contains an impurity that is considered a probable human carcinogen, meaning long-term exposure could potentially increase the risk of cancer. Because these medications are used for chronic conditions like high blood pressure, patients should not stop taking them without an immediate alternative treatment.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.